Logo

AstraZeneca and Merck’s Lynparza (olaparib) Receive NMPA’s Approval as 1L Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer

Share this
AstraZeneca and Merck’s Lynparza (olaparib) Receive NMPA’s Approval as 1L Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer

AstraZeneca and Merck’s Lynparza (olaparib) Receive NMPA’s Approval as 1L Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer

Shots:

  • The approval was based on the P-III (PAOLA-1) trial evaluating Lynparza + bevacizumab vs bevacizumab alone in patients with newly diagnosed advanced FIGO stage III-IV high-grade serous or endometroid ovarian, fallopian tube, or peritoneal cancer
  • The results showed an improvement in PFS while the safety & tolerability profile was consistent with prior clinical trials with no new safety signals
  • The 5yr. analysis of the (PAOLA-1) trial showed m-OS (56.5mos. vs 51.6mos.). In an exploratory subgroup analysis of HRD+ patients, improvement in OS with a 38% reduction in risk of death. The therapy was approved in the US, EU & multiple other countries for the same indication & is currently under regulatory review in other countries globally

Ref: Businesswire | Image: AstraZeneca

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions